The Trump administration announced impending 100% tariffs on branded pharmaceutical imports effective October 1, with exemptions for companies breaking ground on U.S.-based manufacturing facilities. This aggressive tariff policy follows a broad Section 232 investigation into national security implications of drug import reliance. Pharmaceutical companies have responded by accelerating onshoring efforts, though uncertainties remain regarding tariff scope and impact amidst ongoing trade negotiations and multifaceted industry responses. Stakeholders monitor evolving regulatory and market dynamics closely as these measures may affect drug pricing and availability.